DrugPatentWatch Database Preview

Details for Patent: 7,973,040

Which drugs does patent 7,973,040 protect, and when does it expire?

Patent 7,973,040 protects ZEPATIER and is included in one NDA.

This patent has forty-four patent family members in thirty-six countries.

Summary for Patent: 7,973,040

Title:	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Abstract:	The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. ##STR00001##
Inventor(s):	Harper; Steven (Rome, IT), Summa; Vincenzo (Rome, IT), Liverton; Nigel J. (Harleysville, PA), McCauley; John A. (Maple Glen, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ) Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA (Rome, IT)
Application Number:	12/504,955
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,973,040

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Merck Sharp Dohme	ZEPATIER	elbasvir; grazoprevir	TABLET;ORAL	208261-001	Jan 28, 2016		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y		TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,973,040

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,080,654	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,973,040

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072588	➤ Sign Up
Australia	2009274190	➤ Sign Up
Canada	2731177	➤ Sign Up
China	102159285	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,973,040

For more information try a trial or see the plans and pricing